Drug tumor therapy

Urothelial carcinoma of the urinary bladder is a chemosensitive tumor. In the metastatic stage, chemotherapy is the only treatment option with survival benefits for patients.

Cisplatin-based chemotherapy in combination with gemcitabine (CG) is the current first-line standard therapy with an acceptable or more favorable side effect profile compared to the older therapy regimens. Unfortunately, treatment with cisplatin is only feasible in patients with a good general condition and good kidney function.

As an alternative, a combination with carboplatin and gemcitabine or therapy with gemcitabine alone has been offered to date. In the event of disease progression with cisplatin and gemcitabine, treatment with a vinca alkaloid called vinflunine has been available as a second-line therapy since 2009.

A new approach is immunotherapy. This is a promising new option for patients which, under certain conditions, can be used instead of or after chemotherapy. This therapeutic approach uses the body's own immune system to attack the tumor cells. We are happy to offer detailed advice on this in our Clinical Department. In addition, we test the tumour tissue for certain molecular changes in order to further optimize and individualize our therapy planning. For some patients, it is also possible to include them in clinical trials and thus to new drugs with a potentially more favorable spectrum of efficacy.

We will be happy to advise you on this in our oncology consultation hours.
⇒ every Wednesday 9:00 am - 3:00 pm